Скачать или смотреть Why Your Gene Therapy Tech Transfer Fails (A Lesson from Outside Pharma)

In the high-stakes world of cell and gene therapy, we assume our challenges are unique. But what if the biggest threat to your tech transfer is a universal problem your team is blind to?


In this episode of the ⁠Method Made⁠ podcast, Nicholas talks with David Horesh, a CEO who witnesses the same critical communication failure across dozens of industries—from aerospace and defense to cutting-edge biotech. The problem? Scientists and engineers are not speaking the same language, and it's killing innovation.


David's cross-domain experience provides a unique set of "meta-lessons" for the cell and gene therapy space. We funnel his global insights to reveal what CGT teams can learn from mistakes made in entirely different fields.


This episode is a masterclass for CGT professionals on:
The Universal Blind Spot: Recognizing the hidden language gaps that even the most specialized teams take for granted.
Beyond Pharma: How communication breakdowns in mining and quantum physics offer a blueprint for what to fix in your lab.
De-Risking Your Tech Transfer: Why understanding this universal communication flaw is a critical de-risking strategy for scaling therapies from R&D to manufacturing.
The Real Root Cause: Moving beyond SOPs to see how these language gaps create the operational friction that stalls your timeline before a process is ever documented.



If you work in cell and gene therapy, this conversation offers an invaluable outside perspective. It exposes the fundamental communication challenges you didn't know you had and provides a new framework for ensuring your science translates flawlessly into scalable manufacturing.